Rheumatoid Arthritis News

More than 620 registered attendees from 45 states and 11 countries are traveling to Destin, Florida, this week for the 2019 Congress of Clinical Rheumatology, scheduled for May 2 to 5, according to David McLain, MD, FACP, FACR, where they will learn about a wide range of topics from speakers they may not hear anywhere else.

Sexual dysfunction is highly prevalent among men and women with inflammatory arthritis, with diseases-related factors impacting fluctuations in sexual function and reduced sexual desire, according to data published in Arthritis Care & Research.

The FDA has approved the second biosimilar to etanercept, etanercept-ykro, for all eligible indications of the biologic product, according to an FDA press release.

Tofacitinib, either at 5 mg or 10 mg twice daily, maintains its safety profile for at least 9.5 years, with sustained efficacy for at least 8 years in rheumatoid arthritis, according to data from a long-term extension study published in Arthritis Research & Therapy.

Women with higher long-term levels of physical activity are at a lower risk for rheumatoid arthritis, according to data published in Arthritis & Rheumatology.

Case Presentation:

A daily 40-mg regimen of atorvastatin is safe and produced a significantly greater reduction in LDL cholesterol than placebo among patients with rheumatoid arthritis, according to data published in Arthritis & Rheumatology.

The application of a device that uses vibration to stimulate the cymba concha on the external ear can inhibit the production of TNF, IL-1 beta, and IL-6 in healthy individuals, as well as improve symptoms in patients with rheumatoid arthritis, according to data published in Bioelectronic Medicine.

This ripping yarn delves into the history of tumor necrosis factor in relation to rheumatoid arthritis with emphasis on the original studies that set the stage for the use of TNF inhibition in RA.

Among patients with rheumatoid arthritis, tocilizumab was associated with a decreased risk for major adverse cardiovascular events, compared with TNF inhibitors, whereas conventional synthetic disease-modifying antirheumatic drugs may be linked with an increased risk, according to recent data in Arthritis Care & Research.